Formycon 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Stefan Glombitza

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	6.9yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	8.5yrs

최근 관리 업데이트

Recent updates

CEO

Stefan Glombitza (58 yo)

6.9yrs

테뉴어

Dr. Stefan Glombitza has been the Chief Operating Officer and Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza has extensive e...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stefan Glombitza	CEO, COO & Member of Executive Board	6.9yrs	데이터 없음	데이터 없음
Friedrich-Wilhelm Steinweg	Co-Founder	no data	데이터 없음	데이터 없음
Nicolas Combe	Co-Founder	no data	데이터 없음	데이터 없음
Enno Spillner	CFO & Member of Management Board	less than a year	데이터 없음	데이터 없음
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	1.2yrs	데이터 없음	데이터 없음
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	1.3yrs	데이터 없음	데이터 없음
Sabrina Muller	Senior Manager of Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: FYBD 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bernhard Hampl	Member of Advisory Board	9.5yrs	데이터 없음	데이터 없음
Gerhard Schaefer	Member of Advisory Board	9.8yrs	데이터 없음	데이터 없음
Olaf Stiller	Chairman of Supervisory Board	13.7yrs	데이터 없음	데이터 없음
Peter Wendeln	Deputy Chairman of Supervisory Board	13.7yrs	데이터 없음	데이터 없음
Johannes Buchner	Member of Advisory Board	7.6yrs	데이터 없음	데이터 없음
Thomas Siklosi	Member of Advisory Board	5.1yrs	데이터 없음	데이터 없음
Klaus Rohrig	Member of Supervisory Board	2.8yrs	데이터 없음	데이터 없음
Wolfgang Essler	Member of the Supervisory Board	less than a year	데이터 없음	데이터 없음

8.5yrs

평균 재임 기간

경험이 풍부한 이사회: FYBD 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.

Formycon 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Formycon AG Appoints Colin Bond as Director

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

New 90-day high: €47.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간